title: Recurrent drug-induced ANCA vasculitis in a patient with Crohn's colitis treated with infliximab: a potential contraindication to immunosuppressive therapy.
authors.affiliation: Departments of General Colorectal Surgery, Keck Medical Center of the University of Southern California, Los Angeles, California, USA. david.rosen@med.usc.edu
authors.forename: David R
authors.initials: DR
authors.lastname: Rosen
authors.forename: Kyle G
authors.initials: KG
authors.lastname: Cologne
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Popek
authors.forename: Brian C
authors.initials: BC
authors.lastname: Sung
authors.forename: Adrian E
authors.initials: AE
authors.lastname: Ortega
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Senagore
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003082:Colectomy / Q000379:methods; D000075202:Contraindications; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006111:Graves Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007081:Ileostomy / Q000379:methods; D007166:Immunosuppressive Agents; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014657:Vasculitis / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab